Patent ID: 11885807
Assignee: AUTOLUS LIMITED
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC A  C  G

Claim 2:
3. A method of selectively depleting TRBC2 positive malignant T-cells without depleting the entire T-cell compartment in a human subject, the method comprising:
determining whether a malignant T cell in a sample containing T cells from the subject expresses TRBC2, and
selectively depleting malignant and normal T-cells in the subject that express TRBC2 by administering to the subject an agent that selectively binds to TRBC2 and that depletes said malignant and normal T-cells, wherein the agent is an engineered T-cell expressing a CAR that selectively binds to TRBC2 and that comprises: (i) a spacer comprising an IgG1 hinge or a CD8 stalk, and (ii) an endodomain comprising a CD28 co-stimulatory component and a CD3-Zeta component.